Parkinson’s Disease

Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s 3 disease: a systematic review of preclinical and clinical evidence

Parkinson's Disease, Probiotics, Prebiotics and Symbiotics /

Findings from preclinical studies suggest that treatment with probiotics increased glucose metabolism (increased secretion of glucagon-like peptide-1), reduced peripheral and central inflammation (reduced interleukin-6 and tumor necrosis factor-α (TNF-α)), reduced peripheral and central oxidative stress (reduced peripheral superoxide anion levels and increased central antioxidant glutathione levels), decreased neurodegeneration (increased numbers of tyrosine hydroxylase dopaminergic neurons […]

Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s 3 disease: a systematic review of preclinical and clinical evidence Read More »

Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis

Biomarkers, Parkinson's Disease, Pre-PD /

Currently, there is no objective molecular or biochemical test for PD; its diagnosis is based on clinical criteria, mainly by cardinal motor symptoms, which manifest when patients have lost about 60–80% of dopaminergic neurons. Therefore, it is urgent to establish a panel of biomarkers for the early and accurate diagnosis of PD. Once the disease

Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis Read More »

Dietary intake and plasma levels of polyunsaturated fatty acids in early-stage Parkinson’s disease

Diet and Exercise, Parkinson's Disease, Pre-PD /

In a case–control study with 38 patients with PD and 33 controls, we assessed dietary intake using food frequency questionnaires and simultaneously measured the plasma levels of five PUFA. No differences were observed in dietary total energy and lipid intake, including PUFA, between patients with PD and controls. However, α-linolenic acid (ALA), linoleic acid (LA),

Dietary intake and plasma levels of polyunsaturated fatty acids in early-stage Parkinson’s disease Read More »

Boxing vs Sensory Exercise for Parkinson’s Disease: A Double-Blinded Randomized Controlled Trial

Diet and Exercise, Parkinson's Disease /

A significant interaction effect between groups and time were observed F(1, 39) = 4.566, P = .036, where the sensory group improved in comparison to the boxing group. Post hoc analysis revealed that in comparison to boxing, the effects of exercise did not wear off at washout (week 20) P < .006. Conclusion. Future rehabilitation

Boxing vs Sensory Exercise for Parkinson’s Disease: A Double-Blinded Randomized Controlled Trial Read More »

Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease

Biomarkers, Parkinson's Disease, Pre-PD /

Brain-derived EVs are able to cross the blood-brain barrier,protecting their payload from enzymatic degradation, and are easily recovered from biofluids. Interestingly, EVcontent is strongly influenced by the specific pathophysiological status of the donor cell. In this manuscript, therole of EVs as source of novel PD biomarkers is discussed, providing all recent findings concerning relevantproteins and

Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease Read More »

The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease

ENS, Parkinson's Disease /

The present manuscript is dedicated to identifying various neuronal cytotypes belonging to ENS in baseline conditions. The second part ofthe study provides evidence on how these very same neurons are altered during Parkinson’s disease.In fact, although being defined as a movement disorder, Parkinson’s disease features a number ofdegenerative alterations, which often anticipate motor symptoms. Among

The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease Read More »

REM Sleep Behavior Disorder as a Pathway to Dementia: If, When, How, What, and Why Should Physicians Disclose the Diagnosis and Risk for Dementia

Dementia - Lewy Bodies, Parkinson's Disease, Pre-PD /

We provide an approach to risk disclosure for patients with iRBD. Patients should be asked if they want to know about future risks. If so, disclosure should be patient centered, focusing on what might happen. Discussion should occur early to give patients time to prepare for the future and consider participating in research. CLICK TO

REM Sleep Behavior Disorder as a Pathway to Dementia: If, When, How, What, and Why Should Physicians Disclose the Diagnosis and Risk for Dementia Read More »

Temporal trajectory of biofluid markers in Parkinson’s disease

A-Synuclein, Biomarkers, Parkinson's Disease, Pre-PD /

At baseline, PD patients showed lower CSF α-syn, Aβ, t-tau and p-tau levels than those of the controls. In all PD patients, CSF α-syn and Aβ decreased in a negative exponential pattern before the onset of motor symptoms, whereas CSF t-tau and p-tau, and serum NfL increased. Patients with cognitive impairment exhibited faster decline of

Temporal trajectory of biofluid markers in Parkinson’s disease Read More »

Neuroprotective effect of Lactobacillus plantarum DP189 on MPTP-induced Parkinson’s disease model mice

Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics /

The results indicated that L. plantarum DP189 improved behavioral ability and increased the levels of 5-hydroxytryptamine and dopamine of PD mice. L. plantarum DP189 significantly increased the positive rate of tyrosine hydroxylase cells. L. plantarum DP189 activated the ERK2 and AKT/mTOR pathways, promoted the expression of Bcl-2, and inhibited the activities of Bax and Caspase 3. The results indicated that L. plantarum DP189

Neuroprotective effect of Lactobacillus plantarum DP189 on MPTP-induced Parkinson’s disease model mice Read More »